{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:28:57Z","timestamp":1789950537202,"version":"4.0.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2016,3,9]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              No data are available on the long\u2010term performance of ultrathin strut biodegradable polymer sirolimus\u2010eluting stents (\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              ). We reported 2\u2010year clinical outcomes of the\n              <jats:styled-content style=\"fixed-case\">BIOSCIENCE<\/jats:styled-content>\n              (Ultrathin Strut Biodegradable Polymer Sirolimus\u2010Eluting Stent Versus Durable Polymer Everolimus\u2010Eluting Stent for Percutaneous Coronary Revascularisation) trial, which compared\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              with durable\u2010polymer everolimus\u2010eluting stents (\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              ) in patients undergoing percutaneous coronary intervention.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              A total of 2119 patients with minimal exclusion criteria were assigned to treatment with\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              (n=1063) or\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              (n=1056). Follow\u2010up at 2\u00a0years was available for 2048 patients (97%). The primary end point was target\u2010lesion failure, a composite of cardiac death, target\u2010vessel myocardial infarction, or clinically indicated target\u2010lesion revascularization. At 2\u00a0years,\n              <jats:styled-content style=\"fixed-case\">target\u2010lesion failure<\/jats:styled-content>\n              occurred in 107 patients (10.5%) in the\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              arm and 107 patients (10.4%) in the\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              arm (risk ratio [\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              ] 1.00, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.77\u20131.31,\n              <jats:italic>P<\/jats:italic>\n              =0.979). There were no significant differences between\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              and\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              with respect to cardiac death (\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              1.01, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.62\u20131.63,\n              <jats:italic>P<\/jats:italic>\n              =0.984), target\u2010vessel myocardial infarction (\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              0.91, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.60\u20131.39,\n              <jats:italic>P<\/jats:italic>\n              =0.669),\n              <jats:styled-content style=\"fixed-case\">target\u2010lesion revascularization<\/jats:styled-content>\n              (\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              1.17, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.81\u20131.71,\n              <jats:italic>P<\/jats:italic>\n              =0.403), and definite stent thrombosis (\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              1.38, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.56\u20133.44,\n              <jats:italic>P<\/jats:italic>\n              =0.485). There were 2 cases (0.2%) of definite very late stent thrombosis in the\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              arm and 4 cases (0.4%) in the\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              arm (\n              <jats:italic>P<\/jats:italic>\n              =0.423). In the prespecified subgroup of patients with\n              <jats:styled-content style=\"fixed-case\">ST<\/jats:styled-content>\n              \u2010segment elevation myocardial infarction,\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              was associated with a lower risk of\n              <jats:styled-content style=\"fixed-case\">target\u2010lesion failure<\/jats:styled-content>\n              compared with\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              (\n              <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n              0.48, 95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.23\u20130.99,\n              <jats:italic>P<\/jats:italic>\n              =0.043,\n              <jats:italic>P<\/jats:italic>\n              <jats:sub>interaction<\/jats:sub>\n              =0.026).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Comparable safety and efficacy profiles of\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">SES<\/jats:styled-content>\n              and\n              <jats:styled-content style=\"fixed-case\">DP<\/jats:styled-content>\n              \u2010\n              <jats:styled-content style=\"fixed-case\">EES<\/jats:styled-content>\n              were maintained throughout 2\u00a0years of follow\u2010up.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Clinical Trial Registration<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">URL<\/jats:styled-content>\n              :\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier:\n              <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n              01443104.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.116.003255","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T02:53:41Z","timestamp":1458096821000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Ultrathin Strut Biodegradable Polymer Sirolimus\u2010Eluting Stent Versus Durable\u2010Polymer Everolimus\u2010Eluting Stent for Percutaneous Coronary Revascularization: 2\u2010Year Results of the BIOSCIENCE Trial"],"prefix":"10.1161","volume":"5","author":[{"given":"Rainer","family":"Zbinden","sequence":"first","affiliation":[{"name":"Department of Cardiology, Triemlispital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kurz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Triemlispital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Vuilliomenet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kantonsspital, Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital, Fribourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weilenmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kantonsspital, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Jamshidi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kantonsspital, Luzern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Eberli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Triemlispital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pilgrim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61220-X"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.683995"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1210816"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002223"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3859"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61038-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.004"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.04.011"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.045"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-1558"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV11I3A53"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002817"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6530"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht570"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/17434440.2014.894458"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"e_1_3_4_20_2","unstructured":"Jensen LO Thayssen P Maeng M Ravkilde J Krussel L Tilsted H Junker A Terkelsen CJ Vein KT Kaltoft A Villadsen AB Aaroe J Berencsi K Jensen SE Hansen KN Kristensen SD Madsen M Botker HE Hansen HS Raungaard B Lassen JF Christiansen EH. Randomised comparison of a sirolimus\u2010eluting stent with a biolimus\u2010eluting stent in patients treated with PCI: the SORT OUT VII trial. Presented at EuroPCR 2015 Paris. 2015. Available at: http:\/\/www.pcronline.com\/Lectures\/2015\/Randomised-comparison-of-a-sirolimus-eluting-stent-with-a-biolimus-eluting-stent-in-patients-treated-with-PCI-the-SORT-OUT-VII-trial. Accessed November 30 2015."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6625"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu210"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372"},{"issue":"8","key":"e_1_3_4_25_2","article-title":"Biodegradable polymer sirolimus\u2010eluting stents versus durable polymer everolimus\u2010eluting stents for primary percutaneous coronary revascularization of acute myocardial infarction","volume":"11","author":"Pilgrim T","year":"2015","unstructured":"Pilgrim T, Piccolo R, Heg D, Roffi M, T\u00fcller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, J\u00fcni P, Windecker S. Biodegradable polymer sirolimus\u2010eluting stents versus durable polymer everolimus\u2010eluting stents for primary percutaneous coronary revascularization of acute myocardial infarction. EuroIntervention. 2015;11(8).","journal-title":"EuroIntervention"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0472-y"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.22017"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61244-1"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV10I12A247"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.003255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:19:54Z","timestamp":1715595594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3,9]]}},"alternative-id":["10.1161\/JAHA.116.003255"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.003255","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]},"assertion":[{"value":"2016-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e003255"}}